Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51% [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Expected to Reach USD 1986.1 Million by 2033, according to a research report published by Spherical Insights & Consulting. Companies Covered: Teva Pharmaceutical Industries Ltd., Cook, Eisai Co Ltd., Bayer AG, Allergan Inc., Taro Pharmaceutical Inc., Pfizer Inc., GlaxoSmithKline Plc., Cigna, Abbott Laboratories, AstraZeneca, Valeant Pharmaceuticals International Inc., Cipla Inc., Sanofi. And other key vendors. New York, United States , June 20, 2024 (GLOBE NEWSWIRE) -- The Global Anal Fissure Treatment Market Size is to Grow from USD 1161.3 Million in 2023 to USD 1986.1 Million by 2033, at a CAGR of 5.51% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4575 A cut or split in the anal canal's lining is called an anal fissure. The most prevalent causes of anal fissures, especially with bowel movements, are anal pain and rectal bleeding. A fissure is typically caused by anal trauma, particularly when straining to pass firm fe
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Epinephrine Autoinjectors Industry Research Business Report 2024 Featuring ALK-Abello, Bausch + Lomb, Emerade, Teva Pharmaceutical [Yahoo! Finance]Yahoo! Finance
- FTC weighs in on reverse-payment generic delay case involving Gilead, Teva [Seeking Alpha]Seeking Alpha
- Blue Wolf Capital to Create New CDMO Platform [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia [Financial Post (Toronto, Ontario, Canada)]Financial Post
TEVA
Earnings
- 7/31/24 - Beat
TEVA
Sec Filings
- 9/4/24 - Form 4
- 8/14/24 - Form 144/A
- 8/14/24 - Form 144/A
- TEVA's page on the SEC website